Botulinum toxin for adult spasticity after stroke or non-progressive brain lesion

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Lyons, Bernadette E ^a   Moore, Peter ^b   Bhakta, Bipin B ^c   Bamford, John M ^d   Cardwell, Chris R ^e   Logan, Ian D ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; PRIORITY JOURNAL; RETRACTION NOTICE;

EID: 85048463315     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002926.pub3     Document Type: Article

References (15)

1. Barnes M, Bhakta B, Moore P, Richardson D, Salisbury C, Thornton H, et al.The management of adults with spasticity using botulinum toxin: a guide to clinical practice. Byfleet, Surrey: Radius Healthcare, April 2001.
2. Higgins JPT, Green S (eds). Formulating the problem. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, Issue 4, 2005.
3. Egger M, Davey, Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
4. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
5. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
6. Krishnan RV. Botulinum toxin: from spasticity reliever to a neuromotor relearning tool. International Journal of Neuroscience 2005;115:1451-67.
7. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
8. Royal College of Physicians Working Party. Concise guidelines to good practice. Guidelines for the use of botulinum toxin in the management of spasticity in adults. Salisbury, UK: Royal College of Physicians of London, July 2002.
9. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
10. Skeil DA, Barnes MP. The local treatment of spasticity. Clinical Rehabilitation 1994;8:240-6.
11. Thompson A, Jarret L, Lockley L, Marsden J, Stevenson V. Clinical management of spasticity. Journal of Neurology, Neurosurgery and Psychiatry 2005;76(4):459-63.
12. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, et al.Use of botulinum toxin type A in the management of adult spasticity. A European consensus statement. Europa Medicophysica 2004;40:83-4.
13. Whitehead A. Meta-analysis of controlled clinical trials (Statistics in practice). Chichester, UK: John Wiley and Sons Ltd, 2002.
14. World Health Organization. International classification of functioning. www.who.int/classifications/icf/en/ (latest accession date January 2007).
15. Young A. Spasticity: a review. Neurology 1994;44 Suppl 9:13-9.